Moneyshot: We just need it to happen now ;)

Zenith’s unique oncology approach has been advanced to Phase 2b combination therapy trials in the following diseases while demonstrating its positive biological effects on;
 Metastatic Castrate Resistant Prostate Cancer (mCRPC) – ZEN-3694 in combination with Pfizer’s Enzalutimide prostate cancer drug – Phase 2b
 Triple Negative Breast Cancer (TNBC) in combination with Pfizer’s PARP inhibitor and in collaboration with Pfizer. Phase 2 is ongoing• The following indications are already in planning for development with major pharmaceutical companies with planned launches in 2020 & 2021.
 ZEN-3694 and a PARP inhibitor for all Breast cancers
 ZEN-3694 and a PARP inhibitor for Ovarian cancers
 ZEN-3694 and a PARP inhibitor for Prostate cancer
 ZEN-3694 in a triple combination with a Merck and a Pfizer drug
 ZEN-3694 and a checkpoint inhibitor sponsored by a federal group• Post the first prostate cancer trial which was paid for by Zenith, the balance are being or will be paid for in part or whole by the corresponding partners as ZEN-3694 clearly has the potential to expand their existing and future revenues.